Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting

References

• Semple D, Smyth R. Oxford Handbook of Psychiatry. 3rd ed. Oxford: Oxford University Press; 2013.
   Google Scholar
• Hodgson RE, Lewis M, Boardman AP. Prediction of readmission to acute psychiatric units. Soc Psychiatry Psychiatr Epidemiol. 2001;36(6):304–309.11583461
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.27732772
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.24229745
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.23256986
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692–699.15056516
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Thompson A, Carmody T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007;58(6):844–847.17535946
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179(04):290–299.11581108
   PubMedGoogle Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693.28593216
   PubMed Web of Science ®Google Scholar
• Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64(Suppl 16):S14–S17.
   PubMed Web of Science ®Google Scholar
• Wing JK, Beevor AS, Curtis RH, et al. Health of the nation outcome scales (HoNOS). Research and development. Br J Psychiatry. 1998;172:11–18.9534825
   PubMed Web of Science ®Google Scholar
• Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image study. Eur Psychiatry. 2016;37:43–48.27447102
   PubMed Web of Science ®Google Scholar
• Taylor DM, Sparshatt A, Amin F, et al. Aripiprazole long-acting injection – a mirror image study of its effects on hospitalisation at one year. J Psychopharmacol. 2017;31(12):1564–1569.29039241
   PubMed Web of Science ®Google Scholar
• Hodgson re, Lewis M, Boardman AP. The prediction of in-patient length of stay for acute psychiatric admissions. J Ment Health. 2000;9(2):145–153.
   Google Scholar
• Hodgson R, Adeyemo O. Physical examination performed by psychiatrists. Int J Psychiatry Clin Pract. 2004;8(1):57–60.24937585
   PubMed Web of Science ®Google Scholar
• Boardman AP, Hodgson RE, Lewis M, Allen K. North Staffordshire community beds study: longitudinal evaluation of psychiatric in-patient units attached to community mental health centres. I: methods, outcome and patient satisfaction. Br J Psychiatry. 1999;175(01):70–78.10621771
   PubMedGoogle Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.23810019
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.26232241
   PubMed Web of Science ®Google Scholar
• Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections V. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry. 2009;52:S20–28.
   Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16(7):917–925.23663091
   PubMedGoogle Scholar
• Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14(1):53–62.24917233
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685–697.20615933
   PubMed Web of Science ®Google Scholar
• Newcomer JM. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):S1–S93.
   PubMed Web of Science ®Google Scholar
• Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the ziprasidone observational study of cardiac outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193–201.21041245
   PubMed Web of Science ®Google Scholar
• Hodgson R, Bushe C, Hunter R. Measurement of long-term outcomes in observational and randomised controlled trials. Br J Psychiatry. 2007;50(Suppl):S78–S84.
   Google Scholar
• Faries DE, Nyhuis AW, Ascher-Svanum H. Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc. 2009;7(1):11.19473545
   PubMedGoogle Scholar
• Taylor D, Olofinjana O. Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014;29(4):229–234.24419004
   PubMed Web of Science ®Google Scholar